The U.S. FDA granted accelerated approval to Modeyso for patients with diffuse midline glioma with an H3 K27M mutation with progressive disease. The U.S. Food and Drug Administration (FDA) has granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback